Silver Book Fact

Use of an epidermal growth factor inhibitor in the treatment of metastatic colon cancer patients without the KRAS gene mutation saw survival rates of 15.6 months, compared to 5.6 months in those without the mutation.

Lievre, A, J Bachet, V Boige, A Cayre, D LeCorre, E Buc, et al. KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab. J Clin Oncol. 2008; 26(3): 374-9. http://www.ncbi.nlm.nih.gov/pubmed/18202412

Reference

Title
KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab
Publication
J Clin Oncol
Publication Date
2008
Authors
Lievre, A, J Bachet, V Boige, A Cayre, D LeCorre, E Buc, et al
Volume & Issue
Volume 26, Issue 3
Pages
374-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Decline in Cancer Death Rates in Men
     
  • Use of tamoxifen, a drug used to treat breast cancer, has resulted in a direct cost savings of $41,372 per year of life gained in women 35- to 49-years-old, $68,349…  
  • Widespread use of telomerase inhibitors could result in a 50% cure rate and a 25% prolongation of life for 50% of eligible patients with solid tumors.  
  • According to the Pharmaceutical Research and Manufacturers of America, a medicine to fight breast cancer is currently in the pipeline. It targets the Bcl-2 protein, which appears to contribute…  
  • Pathogens cause around two million cancer cases worldwide each year. Ninety percent of these cases are attributable to Helicobacter pylori (H Pylori), hepatitis B virus (HBV), hepatitis C virus (HCV),…